© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Prostate Cancer | Clinical
PSMA Radioligand Therapy Generates Excitement in Prostate Cancer Treatment Paradigm
December 04, 2020
Ulka Vaishampayan, MD, discusses the excitement surrounding PSMA radioligand therapy in the prostate cancer space.
Olaparib Treatment Leads to Significant Survival Improvement in Patients with mCRPC
December 04, 2020
A significantly longer overall survival was observed with olaparib in patients with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM, compared with those who received enzalutamide or abiraterone plus prednisone, according to research presented at the 21st Annual Meeting of the Society of Urologic Oncology.
Lower Risk of Death Observed With Enzalutamide in Patients with nmCRPC
December 04, 2020
Treatment with enzalutamide in combination with androgen deprivation therapy led to a clinically meaningful decrease in the risk of death for patients with non-metastatic castration resistance prostate cancer.
Understanding the Various Biomarker Settings for Metastatic Prostate Cancer
December 04, 2020
In a presentation during the 21st Annual Meeting of the Society of Urologic Oncology, Kara N. Maxwell, MD, PhD, expanded upon the available biomarkers for use in prostate cancer and how they can be applied at various points and for guiding toward which treatments can improve care of patients with prostate cancer.
Enzalutamide Shows PFS Benefit Across Subgroups of nmCRPC
December 03, 2020
Enzalutamide achieved both an improvement in progression-free survival and an increase in time to PSA progression compared with bicalutamide as treatment of patients with nonmetastatic castration-resistant prostate cancer.
Exploring PSMA Therapies in Prostate Cancer
December 03, 2020
Declan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
First PSMA-Targeted PET Drug for Prostate Cancer Approved by FDA
December 02, 2020
The FDA approved Gallium 68 PSMA-11 as the first ever drug for PET imaging of PSMA positive lesions in men with prostate cancer.
PSMA Plays Important Role in the Detection of Prostate Cancer
December 02, 2020
Naomi Haas, MD, discusses the importance of using PSMA, an antigen that is expressed on the cell surface, for the detection of prostate cancer.
A 66-Year-Old Man With Metastatic Castrate-Sensitive Prostate Cancer
December 02, 2020
Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.
RV001 Granted FDA Fast Track Designation for Treatment of Prostate Cancer
November 25, 2020
The FDA granted a Fast Track designation to RV001 for the potential treatment of patients with prostate cancer.